The thesis

Eli Lilly sells the leading approved GLP-1 drugs in Mounjaro and Zepbound, and obesity demand now drives its entire growth engine. Revenue grew 47.7 percent year over year, gross margin sits at 83.4 percent, and net margin reaches 33.5 percent, fundamentals any growth company would envy. Analysts rate the stock a consensus buy, but our conviction model scores it only 35 out of 100, a watchlist signal that clashes with that optimism. The tension is price: at 42.7 times earnings, the market already assumes the bull case, leaving little room for stumble.

Why now

US Zepbound revenue grew 122 percent year over year in Q4 2025 per Lilly investor relations, proof the obesity franchise is still accelerating rather than maturing. With growth this steep already priced into a 42.7 times earnings multiple, the next quarterly report decides whether the premium holds.

What to watch

Watch quarterly US Zepbound and Mounjaro revenue growth against the 122 percent Zepbound benchmark; any step-down tests the multiple directly. Watch competitor obesity trial readouts and pricing concessions over the next one to three quarters for pressure on gross margin.

Key risks

Valuation is the first risk: a 42.7 times multiple collapses if revenue growth decelerates even modestly from 47.7 percent. Competitive pipeline risk is the second: rival obesity drugs or next-generation therapies could erode pricing power behind that 83.4 percent gross margin. The inactive risk-on rotation signal means macro support is absent, so multiple compression would hit without a broad market tailwind.

Theme exposure

Upcoming catalysts